GGrantIndex
← Leaderboards

Sulggi Angela Lee

University Of California, San Francisco

$11,887,064
Attributed
$15,009,984
Total exposure
9
Grants
7
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $4.9M · FY201425
$5M$3.8M$2.5M$1.3M$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$15,009,984 · 9

By mechanism

R01$6,352,496 · 3
R61$2,714,521 · 1
RM1$2,331,737 · 1
R33$1,702,671 · 1
K23$908,334 · 1
R56$794,045 · 1

Most similar at University Of California, San Francisco

Same institution · by research overlap

Others in their field

Top investigators on “Virus

Research focus

VirusInflammationSamplingCellsFutureAntiretroviral TherapyImmune System DiseasesIn VivoSignal TransductionPathway InteractionsGenetic TranscriptionCd4 Positive T LymphocytesPlasmaGeneticCytokineImmuneGenesViralBloodProtein ExpressionChronicImmune ResponseImmunologicsResidual State

Grant awards (21)

In Vivo Imaging and Post-Mortem Study of Methamphetamine Use on Immune Dysfunction and HIV Reservoir Transcription among People with HIV on ART$2,331,737
RM1 · FY2025 · DA
STudy of Acute HIV for investiGating Eradication Strategies (STAGES): The role of IL-10 and IFN signaling$856,202
R01 · FY2025 · AI · contact PI
Short-term and long-term effects of methamphetamine exposure on residual viral transcription during treated HIV disease$822,868
R33 · FY2025 · DA · contact PI
Methamphetamine Activation of Inflammasome and Altered immunity in HIV (MAIA) Study$715,455
R01 · FY2025 · DA
ACCOMPLISH (Applied Coaching of COMPutational Learners In Substance use and HIV) Mentoring Program$206,180
K24 · FY2025 · DA · contact PI
Short-term and long-term effects of methamphetamine exposure on residual viral transcription during treated HIV disease$879,803
R33 · FY2024 · DA · contact PI
STudy of Acute HIV for investiGating Eradication Strategies (STAGES)$794,045
R56 · FY2024 · AI · contact PI
Methamphetamine Activation of Inflammasome and Altered immunity in HIV (MAIA) Study$740,880
R01 · FY2024 · DA
Host genetic predictors of plasma IL-1b levels and pharmacogenomics of in vivo IL-1b blockade during treated HIV disease$806,398
R01 · FY2023 · AI · contact PI
Host genetic predictors of plasma IL-1b levels and pharmacogenomics of in vivo IL-1b blockade during treated HIV disease$806,285
R01 · FY2022 · AI · contact PI
Short-term and long-term effects of methamphetamine exposure on residual viral transcription during treated HIV disease$943,730
R61 · FY2021 · DA · contact PI
Host genetic predictors of plasma IL-1b levels and pharmacogenomics of in vivo IL-1b blockade during treated HIV disease$804,532
R01 · FY2021 · AI · contact PI
Host genetic predictors of plasma IL-1b levels and pharmacogenomics of in vivo IL-1b blockade during treated HIV disease$806,131
R01 · FY2020 · AI · contact PI
Short-term and long-term effects of methamphetamine exposure on residual viral transcription during treated HIV disease$958,404
R61 · FY2019 · DA · contact PI
Host genetic predictors of plasma IL-1b levels and pharmacogenomics of in vivo IL-1b blockade during treated HIV disease$816,613
R01 · FY2019 · AI · contact PI
Short-term and long-term effects of methamphetamine exposure on residual viral transcription during treated HIV disease$812,387
R61 · FY2018 · DA · contact PI
A pharmacogenomics study of HIV latency: the role of PD-1 signaling$164,430
K23 · FY2018 · GM · contact PI
A pharmacogenomics study of HIV latency: the role of PD-1 signaling$185,976
K23 · FY2017 · GM · contact PI
A pharmacogenomics study of HIV latency: the role of PD-1 signaling$185,976
K23 · FY2016 · GM · contact PI
A pharmacogenomics study of HIV latency: the role of PD-1 signaling$185,976
K23 · FY2015 · GM · contact PI
A pharmacogenomics study of HIV latency: the role of PD-1 signaling$185,976
K23 · FY2014 · GM · contact PI